Evaluation for clinical utilization of anti-inflammatory agents in spinal cord ischemia.

点击翻译按钮获取中文摘要

We investigated whether the ischemic spinal cord injury in rabbits was reduced by infliximab, an anti- tumor necrosis factor-alpha agent. We assigned rabbits to three groups (n=5, expect high dose infliximab group); a control group, low dose infliximab group (5mg/kg), high dose infliximab group (10mg/kg). Spinal cord ischemia was produced by occluding the abdominal aorta for 15 min. After the reperfusion, hindlimb motor function (score range: 4, normal to 0, paraplegia) was assessed daily for 7 days, and then the number of normal neurons in the anterior spinal cord was counted. There were no significant intergroup differences in neurological scores. On the other hand, the numbers of normal neurons of low dose infliximab group had significantly more than a control group. This results indicate that low dose infliximab(5mg/kg) may protect ischemic spinal cord injury, but clinical utilization of infliximab for spinal cord ischemia should be discreet.